Viemed is transforming from a high-acuity respiratory rental provider into a diversified, capital-light home healthcare platform with strong recurring revenue, improving free cash flow, and meaningful upside if execution continues.
Viemed Healthcare, Inc. operates as a leading provider of technology-enabled, home-based healthcare solutions and chronic disease management services within the United States.[1, 2] The company serves as a vital post-acute link, clinical practitioner network, and digital monitoring partner connecting patients, physicians, and health payors.[3, 4] The core business is structured around high-acuity in-home respiratory care, specifically non-invasive ventilation (NIV) therapies for patients suffering from advanced stages of chronic obstructive pulmonary disease (COPD) and chronic respiratory failure.[3, 5] The company has leveraged this specialized platform to successfully diversify into several adjacent, high-margin, and capital-light service segments, including positive airway pressure (PAP) sleep therapy, portable home oxygen solutions, airway clearance systems, direct-to-home maternal health products, and healthcare professional staffing services.[6, 7, 8]
Revenue is generated primarily through two distinct economic models: monthly recurring medical equipment rentals and direct equipment or supply sales.[5, 9] Monthly rental income represents the foundation of the company's financial model, accounting for 68% of total revenue in the first quarter of 2026.[9] This is driven by high-acuity ventilator rentals and other home medical equipment (HME) including PAP machines and oxygen concentrators.[9, 10] Direct equipment and supply sales, which accounted for 32% of total revenue in the first quarter of 2026, are driven by recurring sleep therapy resupply shipments (such as masks and filters) and insurance-covered maternal health shipments.[9, 10] Geographically, the company operates across all 50 states, managing a patient base of over 183,000 active individuals.[6]
The core products and services sold by the company include:
* Non-Invasive Ventilation (NIV): The primary service line, utilizing advanced home mechanical ventilators to treat chronic respiratory failure.[11, 12]
* Sleep Therapy Services: High-touch setups of CPAP and BiPAP devices to manage obstructive sleep apnea, paired with an automated sleep resupply program.[5, 9, 13]
* Maternal Health Products: Primarily direct-to-home, insurance-reimbursed breast pumps, postpartum recovery garments, and nursing supplies.[7, 10]
* Oxygen and Airway Clearance: Tankless portable oxygen concentrators, nebulizers, cough assists, and high-frequency chest wall percussion vests.[5, 7]
* Viemed Clinical Staffing: The placement of contract respiratory therapists, nurses, and allied healthcare professionals within hospitals and post-acute care facilities.[6, 7]
The primary customer types consist of post-acute patients suffering from severe chronic pulmonary diseases, sleep apnea sufferers, and pregnant or postpartum women.[3, 5, 10] The company's end markets are rooted in the multi-billion-dollar post-acute care, home medical equipment, and clinical telemedicine sectors.[1, 5] Customers and referral sources choose the company over traditional HME alternatives because of its high-touch clinical model.[5] While standard competitors act as product distributors, the company deploys licensed clinical practitioners directly into patients' homes.[2] This hands-on clinical monitoring drives high compliance rates, improves patient outcomes, and delivers documented reductions in hospital readmissions, creating a highly compelling economic proposition for commercial and government payors.[3, 4]
Evaluating the company's long-term investment case requires analyzing its product economics, competitive moats, market opportunities, and competitive positioning.
The core ventilator rental business operates on a highly clinical, subscription-like model.[5] When an advanced COPD patient is prescribed home NIV, the company provides a high-acuity medical ventilator (such as the Philips Trilogy or ResMed Astral series).[5, 14] These clinical assets are maintained in the patient’s home, with reimbursement managed through monthly rental fees paid by government and private insurers.[5] This segment is capital-intensive, requiring significant upfront inventory investment, but yields steady, high-margin cash flows.[5, 6]
To improve capital efficiency, the company is rapidly scaling its sleep therapy and resupply platform.[10, 15] When a patient is diagnosed with obstructive sleep apnea, they are set up with a PAP device.[10, 13] While the physical machine generates initial rental or sales revenue, the long-term value is driven by the sleep resupply program.[10] Under Medicare and commercial insurance guidelines, patients are eligible to receive replacement masks, filters, and hoses at structured intervals.[5, 10] The company utilizes automated outreach to manage shipments, creating a highly predictable and compounding recurring revenue stream that carries minimal capital expenditure requirements.[9, 10]
In July 2025, the company acquired Lehan’s Medical Equipment, utilizing this brand to launch a national rollout of its maternal health business.[10, 12, 16] The maternal health business represents a high-velocity, asset-light sales model.[7, 10] The company sources insurance-covered breast pumps, compression garments, and postpartum recovery kits and ships them directly to patients.[7, 10] This business bypasses the complex logistics, device maintenance, and heavy CapEx of the rental model, allowing the company to expand its margins and increase its free cash flow conversion.[10, 15]
The company has established a robust, multi-layered competitive moat centered on high switching costs, regulatory scale, and a dense national distribution network:
* Switching Costs: Once a patient is established on a home ventilator under the supervision of a clinical respiratory therapist, the clinical friction of switching to an alternative provider is high.[5] Pulmonologists and sleep clinics prefer to partner with a single provider that offers integrated compliance tracking portals, connected-device monitoring, and reliable local support, creating sticky clinical relationships.[3, 5]
* Scale and Compliance Infrastructure: The regulatory requirements for home respiratory care are demanding.[5, 13] Under the revised National Coverage Determination (NCD) guidelines implemented by CMS, scale providers with advanced compliance tracking, robust billing software, and dedicated legal appeal frameworks hold a major advantage.[13] The company’s specialized infrastructure has enabled a 100% success rate on appealed Medicare Advantage denials at the Administrative Law Judge (ALJ) level, illustrating a key scale advantage.[13]
* Distribution and Payor Networks: Securing in-network status with national and regional payors is a major barrier to entry.[5, 16] The company possesses a broad nationwide payor network that spans thousands of commercial, Medicaid, and Medicare Advantage plans.[5, 16] This extensive insurance coverage, combined with a network of local clinical branches across the country, represents a competitive advantage that regional operators cannot easily replicate.[2, 5]
The addressable market for post-acute respiratory and sleep therapy solutions in the United States remains highly underpenetrated. It is estimated that approximately 25 million people in the United States suffer from COPD.[3, 7] Within this cohort, approximately 10% (2.5 million patients) have advanced Stage 4 COPD, and roughly 50% of those (1.25 million patients) develop chronic respiratory failure, making them primary candidates for home non-invasive ventilation.[3] However, Medicare data reveals that only about 70,000 beneficiaries are currently on home NIV therapy, representing an estimated market penetration rate of only 6%.[3, 7] This indicates a massive, clinically eligible, yet underserved population.[3]
In the sleep segment, the company is capitalizing on a large, high-margin market.[10, 12] The positive airway pressure (PAP) and CPAP mask market is estimated to have a total addressable size of $2.2 billion, expanding at a high-single-digit annualized rate, driven by growing sleep apnea awareness and rising diagnostic rates.[17]
The durable medical equipment (DME) and respiratory care landscape is fragmented but led by a few prominent players. The company’s primary public competitors include AdaptHealth Corp. (AHCO) and Quipt Home Medical Corp. (QIPT).[18, 19, 20]
+---------------------------------------------------------------------------------------+
| COMPETITOR PROFILE COMPARISON |
+---------------------+-------------------------+-------------------------+-------------+
| Feature / Metric | Viemed (VMD) | AdaptHealth (AHCO) | Quipt (QIPT)|
+---------------------+-------------------------+-------------------------+-------------+
| Core Business Focus | High-Acuity Respiratory | Generalist HME / DME | Respiratory |
| Gross Margin (TTM) | ~57% - 58% [9, 12]| ~61% - 64% [18] | ~70% [21]|
| Leverage (Net Debt) | $0M (Net Cash) [6] | Significant [18] | 1.8x [22]|
| Coverage Footprint | National (50 States)| National [20] | Regional |
| Capital Intensity | Low (9%-10.5% CapEx)| Moderate | Moderate |
+---------------------+-------------------------+-------------------------+-------------+
AdaptHealth operates as a massive national generalist distributor.[20, 23] While AdaptHealth possesses superior absolute scale, its volume-driven model lacks the clinical specialization required for complex, high-touch respiratory care.[5] Quipt Home Medical is highly focused on home respiratory care, expanding its footprint through regional acquisitions.[20, 24] Quipt maintains high reported gross margins of approximately 70% [21], but operates with a lower-acuity product mix and relies more heavily on standard HME retail compared to the company’s high-acuity ventilation focus.[5, 9, 24] The company is successfully gaining ground against its peers, particularly in sleep and maternal health, by cross-selling products into its existing national referral networks.[10, 16] By concentrating on specialized high-acuity respiratory care, the company achieves superior EBITDA margins and a highly capital-efficient financial profile relative to generic HME distributors.[6, 12]
A detailed review of the company's financial indicators reveals a business undergoing a structural shift toward a more cash-generative, capital-light operating model.[15]
The latest reported quarter for the company is the first fiscal quarter ended March 31, 2026, which was publicly announced on May 6, 2026.[9, 15]
The company delivered net revenue of $75.4 million (specifically $75,414 thousand) for the first quarter of 2026, representing a strong 28% increase over the $59.1 million reported in the first quarter of 2025.[9, 15] Sequentially, revenue was flat compared to the record $76.2 million generated in the fourth quarter of 2025, which met management’s guidance regarding typical seasonal patterns.[10]
The gross profit for the quarter reached $42.8 million, representing a gross profit margin of 56.8%.[9, 15] While this margin reflects a slight compression from the 60% gross margins seen in prior historical periods due to a shifting revenue mix toward sleep resupply and maternal health sales, gross profitability remains highly resilient.[9, 12]
GAAP net income attributable to the company was $2.6 million (specifically $2,582 thousand), which translated to diluted earnings per share (EPS) of $0.06.[9, 15] Adjusted EBITDA grew 12% year-over-year to $14.3 million (a margin of 19.0%), despite a challenging comparison to the prior-year quarter which benefited from a non-recurring $2.7 million gain on ventilator disposals.[9, 15]
+-------------------------------------------------------------------------------------+
| INCOME STATEMENT HIGHLIGHTS (Q1 2026 VS Q1 2025) |
+------------------------------------+------------------+------------------+----------+
| Metric (USD in Thousands) | Q1 2026 | Q1 2025 | YoY % |
+------------------------------------+------------------+------------------+----------+
| Net Revenue | $75,414 [9] | $59,129 [9] | +27.5% |
| Cost of Revenue | $32,587 [25] | $25,850 [25] | +26.1% |
| Gross Profit | $42,827 [9] | $33,279 [9] | +28.7% |
| Gross Profit Margin | 56.8% [9] | 56.3% [9] | +50 bps |
| SG&A Expenses | $34,792 [15] | $28,425 [25] | +22.4% |
| Operating Income | $4,296 [25] | $3,841 [25] | +11.8% |
| GAAP Net Income (Attributable) | $2,582 [9] | $2,625 [9] | -1.6% |
| Diluted EPS (USD) | $0.06 [9] | $0.06 [9] | 0.0% |
| Non-GAAP Adjusted EBITDA | $14,311 [15] | $12,765 [15] | +12.1% |
+------------------------------------+------------------+------------------+----------+
During the Q1 2026 earnings announcement, the company presented a mixed picture relative to Wall Street forecasts:
* Revenue Performance: The reported net revenue of $75.4 million beat consensus analyst expectations by 1.4%.[26]
* Earnings Performance: GAAP EPS of $0.06 missed consensus analyst expectations of $0.09 by approximately 33%.[9, 26] This earnings miss was driven by higher-than-expected operational, SG&A, and clinical expansion costs during the quarter.[9, 26]
* Guidance Revisions: Concurrently, management narrowed and raised its full-year 2026 revenue guidance to a range of $312 million to $320 million (from the previous range of $310 million to $320 million).[15] Full-year Adjusted EBITDA guidance was reaffirmed at $65 million to $69 million.[15] Crucially, management lowered its net capital expenditures forecast for the full year to 9.0%–10.5% of net revenue (down from the prior range of 10.0%–11.5%), citing an accelerated structural shift toward less capital-intensive service lines.[9, 15]
In the Q1 2026 earnings materials, CEO Casey Hoyt highlighted that the company's diversification and scaling efforts are delivering tangible results.[15] The sleep and maternal health divisions are expanding rapidly, and the core ventilation segment is exhibiting steady underlying referral momentum.[14, 15] Management emphasized that the combination of strong top-line organic growth and a capital-efficient product mix is fundamentally transforming the company's free cash flow profile.[15]
However, the earnings miss had an immediate, negative impact on short-term stock performance.[9, 25] Upon release, the stock experienced a sharp 9.79% premarket decline to $9.38 per share, ultimately finishing the subsequent trading session down approximately 12.2% on elevated trading volume that reached 2.3 times the daily average.[9, 25] Despite this short-term volatility, institutional analyst recommendations remained constructive.[26] Analysts highlighted the company's capital efficiency and cash generation, maintaining a strong positive sentiment with an average consensus target price of $13.00, suggesting that the stock is undervalued.[26, 27]
To fully understand the company's valuation, investors must analyze its fundamental cash flow drivers:
* Compounded Annual Sales Growth: The company has delivered a 26% compounded annual revenue growth rate since its public listing in 2017.[6, 7] This organic momentum is complemented by strategic M&A, such as the Lehan acquisition.[12, 16]
* Free Cash Flow Generation: Free cash flow (FCF) reached $28.1 million in 2025, a 141% increase from $11.6 million in 2024.[16] For the trailing twelve months ended March 31, 2026, free cash flow reached $36.3 million.[15] This improvement is directly tied to the capital-light nature of sleep resupply and maternal health services, which require significantly lower upfront capital expenditure than the core ventilator rental model.[6, 15]
* Pristine Balance Sheet and Capital Returns: As of March 31, 2026, the company maintained a cash balance of $9.8 million against a total outstanding term loan debt of only $9.2 million ($8.3 million long-term and $0.9 million current), representing effectively $0 million in net debt.[6, 15] Backed by an undrawn credit facility of $46 million [15], the company continues to execute on capital returns.[6] During Q1 2026, the company repurchased and cancelled 150,000 common shares at an average price of $9.29 per share.[15]
Evaluating the company's long-term outlook requires assessing its operational, regulatory, and macroeconomic risk factors.
+---------------------------------------------------------------------------------------+
| STRATEGIC RISK MATRIX |
+--------------------------+----------------------------+-------------------------------+
| What Could Go Wrong | Early Warning Signs | Long-Term Thesis Damage |
+--------------------------+----------------------------+-------------------------------+
| Patient attrition | A sequential decline in | A major, flat cut to CMS |
| outpaces setups under | the ventilator patient | reimbursement rates for |
| the strict June 2025 | base below 12,259 [16], | ventilation or PAP therapies |
| NCD guidelines.[13, 28] |
| [14, 29]]. | below 55%.[9, 12] | |
+--------------------------+----------------------------+-------------------------------+
| Integration delays and | Slower-than-expected | Persistent failure to scale |
| commercial friction in | maternal health patient | maternal health or sleep |
| new geographical markets | additions in Q2 and Q3 | resupply, leading to a |
|.[10, 28] | 2026.[10] | permanent return to a high- |
| | | CapEx rental model.[15] |
+--------------------------+----------------------------+-------------------------------+
To evaluate the company’s potential 5-year total return, this scenario analysis models High, Base, and Low outcomes from fiscal year 2026 through fiscal year 2031.
The valuation is based on the following current parameters as of June 2026:
* Current Share Price: $10.40 USD.[32, 33, 34]
* Diluted Share Count: 40.5 million shares.[25]
* Net Debt: Effectively $0 million.[6, 8]
The Base Case assumes steady execution of the company’s diversification strategy. The sleep resupply segment continues to scale, and the maternal health brand is rolled out nationally.[10, 16] The core ventilator business stabilizes and grows at a measured pace as physicians adapt to the June 2025 NCD guidelines.[12, 13]
* Revenue Growth: 5-year revenue CAGR of 12.0%, with revenue expanding from the 2026 projected base of $316.0 million to $565.0 million in Year 5.[12, 15]
* EBITDA / Margins: Adjusted EBITDA margin stabilizes at 21.0% due to operating leverage, resulting in Year 5 Adjusted EBITDA of $118.7 million.[12]
* Earnings and Share Count: Net profit margin stabilizes at 6.2%, leading to Year 5 GAAP net income of $35.0M. Ongoing share buybacks offset equity compensation dilution, reducing the diluted share count to 39.0 million.[15, 30, 31] This yields Year 5 EPS of $0.90 USD.
* Exit Valuation: An EV/EBITDA multiple of 7.5x is applied, reflecting the company’s improved cash flow profile and scale.[12]
* Bridge to Valuation:
$\text{Enterprise Value} = \$118.7\text{ million} \times 7.5 = \$890.3\text{ million}$
Assuming net debt remains at $0 million as free cash flow covers dividends, buybacks, and tuck-in M&A [6, 15], the implied Market Capitalization is $890.3 million.
* Share Price Outcome: Dividing the Market Capitalization by the projected share count yields a Year 5 share price of $22.83 USD.[32]
* Returns: This represents a 5-year total return of 119.5% and an annualized return of 17.0%.[32]
The High Case assumes an accelerated national rollout of maternal health services and stronger sleep resupply patient retention.[10] The core ventilation business experiences a robust recovery as competitor scale limitations drive referral sources to the company.[5, 13]
* Revenue Growth: 5-year revenue CAGR of 16.0%, with net revenue reaching $663.7 million in Year 5.[12, 15]
* EBITDA / Margins: EBITDA margin reaches 22.5% due to scale-driven efficiencies, generating Year 5 Adjusted EBITDA of $149.3 million.[12]
* Earnings and Share Count: Net profit margin reaches 7.0%, generating GAAP net income of $46.5 million. Enhanced free cash flow allows for more aggressive share repurchases, reducing the diluted share count to 37.5 million.[6] This yields Year 5 EPS of $1.24 USD.
* Exit Valuation: A premium EV/EBITDA multiple of 9.0x is applied, reflecting high growth and strong FCF generation.[12]
* Bridge to Valuation:
$\text{Enterprise Value} = \$149.3\text{ million} \times 9.0 = \$1,343.7\text{ million}$
Strong cash generation results in a net cash position (negative net debt) of -$50.0 million, yielding an implied Market Capitalization of $1,393.7 million.
* Share Price Outcome: Dividing the Market Capitalization by the share count yields a Year 5 share price of $37.17 USD.[32]
* Returns: This represents a 5-year total return of 257.4% and an annualized return of 29.0%.[32]
The Low Case assumes persistent regulatory friction from the June 2025 NCD ventilation guidelines, resulting in elevated patient compliance dropouts.[13, 29] Price compression in sleep resupply and regional labor shortages limit profitability.[19, 28]
* Revenue Growth: 5-year revenue CAGR is limited to 5.0%, with net revenue reaching $403.3 million in Year 5.[12, 15]
* EBITDA / Margins: EBITDA margin compresses to 18.0%, resulting in Year 5 Adjusted EBITDA of $72.6 million.[12]
* Earnings and Share Count: Net profit margin drops to 4.5%, yielding GAAP net income of $18.1 million. Suspended share buybacks and LTIP dilution increase the diluted share count to 42.0 million.[30, 31] This yields Year 5 EPS of $0.43 USD.
* Exit Valuation: The EV/EBITDA multiple compresses to 5.0x, reflecting low growth and regulatory risks.[12]
* Bridge to Valuation:
$\text{Enterprise Value} = \$72.6\text{ million} \times 5.0 = \$363.0\text{ million}$
Capital requirements and term loan reliance result in net debt of $10.0 million, yielding an implied Market Capitalization of $353.0 million.
* Share Price Outcome: Dividing the Market Capitalization by the share count yields a Year 5 share price of $8.40 USD.[32]
* Returns: This represents a 5-year total return of -19.2% and an annualized return of -4.2%.[32]
+-----------------------------------------------------------------------------+
| PROJECTED SHARE PRICE TRAJECTORY |
+------------------+----------+----------+----------+----------+--------------+
| Scenario | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 (USD) |
+------------------+----------+----------+----------+----------+--------------+
| High Case | $12.50 | $16.50 | $22.00 | $29.00 | $37.17 [32]|
| Base Case | $11.00 | $13.50 | $16.00 | $19.50 | $22.83 [32]|
| Low Case | $9.50 | $9.00 | $8.80 | $8.50 | $8.40 [32]|
+------------------+----------+----------+----------+----------+--------------+
Integrating the three scenarios with their respective probabilities yields a probability-weighted 5-year share price target:
* $\text{Weighted Price} = (0.55 \times \$22.83) + (0.25 \times \$37.17) + (0.20 \times \$8.40) = \$23.53\text{ USD}$.[32]
* This implies a 5-year total return of 126.3% from the current share price of $10.40 USD, which translates to a compound annual growth rate (CAGR) of 17.7%.[32]
+--------------------------------------------------------------------------------------------------------------------------------------------+
| 5-YEAR SCENARIO TABLE |
+-----------+-----------------------+---------------------+-------------------+---------------------+---------------------+------------------+
| Scenario | Revenue in Year 5 | Margin / EPS | Multiple | Current Price | Implied Year 5 Price| Total / Ann. Ret |
+-----------+-----------------------+---------------------+-------------------+---------------------+---------------------+------------------+
| High Case | $663.7M [12, 15] | 22.5% / $1.24 EPS | 9.0x EV/EBITDA | $10.40 USD [32] | $37.17 USD [32] | 257.4% / 29.0% |
| Base Case | $565.0M [12, 15] | 21.0% / $0.90 EPS | 7.5x EV/EBITDA | $10.40 USD [32] | $22.83 USD [32] | 119.5% / 17.0% |
| Low Case | $403.3M [12, 15] | 18.0% / $0.43 EPS | 5.0x EV/EBITDA | $10.40 USD [32] | $8.40 USD [32] | -19.2% / -4.2% |
+-----------+-----------------------+---------------------+-------------------+---------------------+---------------------+------------------+
| Weighted | $557.1M [12, 15] | 20.8% / $0.88 EPS | 7.3x EV/EBITDA | $10.40 USD [32] | $23.53 USD [32] | 126.3% / 17.7% |
+-----------+-----------------------+---------------------+-------------------+---------------------+---------------------+------------------+
SIGNIFICANT UPSIDE POTENTIAL
Evaluating the company's quantitative performance alongside its qualitative characteristics provides a holistic overview of its operational strength and long-term durability:
Integrating the scores across all ten fundamental areas results in a blended qualitative score of 8.0 / 10.
HIGHLY RESILIENT BUSINESS
Viemed Healthcare is undergoing a structural transition from a high-CapEx, high-acuity home ventilation provider into a capital-light, diversified chronic disease management platform.[5, 6, 15] Its balance sheet is in excellent health, with zero net debt, rising free cash flow, and a reduced CapEx intensity that supports its financial flexibility.[6, 8, 15]
Three key structural catalysts are expected to drive the investment case over the next five years:
* The Sleep Resupply Compounder: The company's PAP patient base grew 57% year-over-year in Q1 2026.[10] As this base continues to expand, the automated, high-margin sleep resupply model is expected to generate predictable recurring revenue.[9, 10]
* Maternal Health Scaling: The national rollout of the maternal health platform, following the Lehan acquisition, offers a fast-growing, asset-light business line.[10, 12, 16] By utilizing existing payor contracts and direct-to-home distribution, the company can grow this segment with minimal capital expenditure.[7, 10]
* Ventilator Referral Recovery: While the June 2025 CMS NCD changes created near-term friction, the market is adapting, and referral pipelines are showing signs of improvement.[13, 14] Over time, the strict compliance and documentation requirements are expected to favor large-scale, highly compliant providers like Viemed, allowing them to gain market share from smaller, resource-constrained competitors.[13]
The primary investment risks include margin compression from the shifting product mix toward sleep and maternal retail sales, regulatory audit friction, and compliance-driven patient dropouts.[9, 14, 28] Nonetheless, given the company's strong historical sales CAGR of 26% since listing and its current valuation of just 5.5x EV/EBITDA on 2026 estimates, the stock appears structurally undervalued.[6, 12]
COMPELLING UNDERVALUED PLATFORM
The company's stock exhibits positive technical strength, currently trading at approximately $10.40 USD.[32, 33, 34] This level is well above its rising 200-day moving average of $8.17 USD and its 50-day moving average of $9.85 USD.[33] Despite a sharp, temporary sell-off in May 2026 triggered by a Q1 EPS miss, the stock has quickly rebounded, supported by consistent share buybacks, positive analyst sentiment, and steady forward expectations.[9, 15, 26] The short-term outlook remains positive, with the stock consolidated above key support levels and poised to test resistance as sequential revenue growth of 3%–5% per quarter is realized through the remainder of fiscal year 2026.[9, 33]
BULLISH PRICE MOMENTUM
View Viemed Healthcare, Inc. (VMD) stock page
Loading the interactive version of this report…